Clinical Trial Update: A Study to Evaluate the Safety and Dosimetry of 68Ga-OncoCAIX in Patients With CAIX-positive Cancer [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating safety and dosimetry of the radiotracer 68Ga-OncoCAIX in CAIX-positive cancer has completed, including patients with clear cell renal…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma

Drugs mentioned

• 68Ga-OncoCAIX

Snippet

Sponsor: Philogen S.p.A. | Conditions: Clear Cell Renal Cell Carcinoma (ccRCC) | Phase 1 | Status: COMPLETED